| Literature DB >> 35169533 |
Chi-Son Kim1, Aletha Akers2, Daenuka Muraleetharan3, Ava Skolnik4, Whitney Garney3, Kelly Wilson3, Aditi Sameer Rao5, Yan Li6,7.
Abstract
Teenage pregnancy is an important public health issue in the United States, presenting significant health and economic risks to adolescents and the society. Health coaching is a potentially effective intervention in preventing teen pregnancy. In 2017, the Children's Hospital of Philadelphia implemented a health coaching program among sexually active teenage girls, which improved their contraceptive continuation rates. However, the cost-effectiveness of the health coaching program is not clear. We developed a microsimulation model of teen pregnancy that can predict the number of teen pregnancies and related birth outcomes. Model parameters were estimated from the literature and the health coaching program. The teen pregnancy model was used to assess how the program could influence direct health care costs and pregnancy outcomes. Our model projected that the health coaching program could prevent 15 teen pregnancies per 1000 adolescents compared to no intervention. The incremental cost-effectiveness ratio (ICER) for the intervention was $309 per pregnancy prevented, which was less than the willingness-to-pay threshold of $4,206 per pregnancy. Thus, the health coaching intervention was cost-effective. Our study provides promising data on the effectiveness and cost-effectiveness of a health coaching intervention to reduce the burden of teen pregnancies. Health practitioners should consider implementing the program for a longer term and at a larger scale.Entities:
Keywords: Community health; Economic evaluation; Health coaching; Teen pregnancy
Year: 2022 PMID: 35169533 PMCID: PMC8829809 DOI: 10.1016/j.pmedr.2022.101716
Source DB: PubMed Journal: Prev Med Rep ISSN: 2211-3355
Fig. 1Structure of the teen pregnancy model.
Model parameters and data sources.
| Parameter | Base Case (%) | Range in sensitivity analysis | Data sources |
|---|---|---|---|
| Obijuru et al. ( | |||
| Implant | 3 | 2.25–3.75 | |
| Intrauterine device | 3 | 2.25–3.75 | |
| DMPA | 13 | 9.75–16.25 | |
| Oral contraceptive pills | 2 | 1.5–2.5 | |
| Patch | 2 | 1.5–2.5 | |
| Condom | 35 | 26.25–43.75 | |
| No method | 42 | 31.5–52.5 | |
| Trussell and Wynn25 | |||
| Implant | 0.05 | 0.0375–0.0625 | |
| Levonorgestrel intrauterine device | 0.2 | 0.15–0.25 | |
| Copper intrauterine device | 0.8 | 0.6–1.0 | |
| DMPA | 6 | 4.5–7.5 | |
| Combined hormonal pill, patch, ring | 9 | 6.75–11.25 | |
| Condom | 18 | 13.5–22.5 | |
| No method | 85 | 63.7–100 | |
| Rosenstock et al. ( | |||
| Nexplanon | 82.2 | ||
| Copper intrauterine device | 76.5 | ||
| Levonorgestrel intrauterine device | 80.6 | ||
| DMPA | 47.3 | ||
| Oral contraceptive pills | 46.7 | ||
| Patch | 40.9 | ||
| Ring | 31 | ||
| Kost et al. ( | |||
| Live birth | 59 | ||
| Spontaneous abortion | 14.4 | ||
| Ectopic pregnancy22 | 0.8 | ||
| The HC3 program | |||
| LARC continuation rate | 60 | ||
| SARC continuation rate | 76.9 | ||
| IBM Micromedex RED BOOK27 | |||
| Implant | $1,068.36 | ||
| Levonorgestrel intrauterine device | $11,117.49 | ||
| Copper intrauterine device | $970.20 | ||
| DMPA | $81.52 | ||
| Oral contraceptive pills | $32.00 | ||
| Patch | $152.69 | ||
| Vaginal ring | $195.16 | ||
| Sonfield et al. ( | |||
| Live birth | $11,015.00 | ||
| Spontaneous abortion (PA) | $1,080.00 | ||
| Ectopic pregnancy (national) | $7,590.00 | Bellows et al. ( |
Live birth period includes prenatal, labor and delivery, and 12 months of infant care.
Baseline cost effectiveness results in 1, 3, and 5 years.
| Costs ($) | No. of pregnancies averted (per 1000 persons) | ICER ($/pregnancy) | Less than WTP | ||
|---|---|---|---|---|---|
| Year 1 | Baseline | 4,579 (4,364–4,793) | |||
| HC3 | 4,584 (4,367–4,799) | 15 | 309 | YES | |
| Year 3 | Baseline | 17,076 (16,669–17,483) | |||
| HC3 | 17,049 (16,635–17,463) | 42 | 630 | YES | |
| Year 5 | Baseline | 29,662 (29,131–30,193) | |||
| HC3 | 29,654 (29,130–30,178) | 72 | 101 | YES |
Notes: Numbers in parentheses are 95% confidence intervals.
HC3 = Health Coaching for Contraceptive Continuation; ICER = incremental cost-effectiveness ratio; WTP = willingness to pay=$4,206.
One-way sensitivity analyses over one year.
| Variable | Baseline (%) | Range (+/- 25%) | Baseline ICER | ICER range |
|---|---|---|---|---|
| SARC continuation rate at HC3 | 60 | 35–85 | 309 | 140–4,492 |
| LARC continuation rate at HC3 | 76.9 | 51.9–100 | 309 | 60–2,121 |
Abbreviation: ICER = incremental cost-effectiveness ratio; SARC = short-acting reversible contraception; LARC = long-acting reversible contraception; HC3 = Health Coaching for Contraceptive Continuation.